Profusa, Inc. received a Nasdaq Compliance Determination Letter confirming it has demonstrated compliance with the Bid Price Rule and Equity Rule. However, the company is subject to a one-year Mandatory Panel Monitor. If Profusa fails to satisfy the equity rule during this period, Nasdaq will issue a delisting determination without offering a cure or compliance plan. The company intends to continue monitoring its compliance with listing requirements. Profusa operates in the digital health industry, pioneering next-generation biosensor technologies.
